Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics

NEW YORK, October 22, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Gilead Sciences, Inc. (NASDAQ: GILD), Amgen Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG), and Insys Therapeutics Inc. (NASDAQ: INSY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On October 17, 2013, Pfizer Inc.'s (Pfizer) stock rose 1.54%, ending the day at $30.26. Over the previous three trading sessions, shares of Pfizer gained 3.10%, outperforming the S&P 500 which gained 1.35% during the same period. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE]

--

Gilead Sciences, Inc. Research Report

On October 16, 2013, Gilead Sciences, Inc. (Gilead) announced three-year (144-week) efficacy and safety results from two key Phase 3 studies (Studies 102 and 103) evaluating the once-daily single tablet regimen Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) among treatment naïve patients with HIV-1 infection. According to Gilead, data revealed that after three years of treatment, Stribild demonstrated comparable efficacy to two standard-of-care HIV regimens, Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Study 102 and a protease inhibitor-based regiment of ritonavir boosted atazanavir plus Truvada® (emtricitabine and tenofovir disoproxil fumarate) in study 103. Commenting on the study results, Jürgen Rockstroh, MD, Professor of Medicine at University of Bonn, Germany, said, "In these large-scale clinical trials, Stribild demonstrated high and durable viral suppression and a favorable safety profile over three years of therapy. These results support Stribild as an important single-tablet treatment option for people starting antiretroviral therapy." The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9898_GILD]

--

Amgen Inc. Research Report

On October 16, 2013, Amgen Inc. (Amgen) announced the appointment of Greg C. Garland, Chairman, President, and CEO of Phillips 66, to the Company's Board of Directors. The Company said that Garland will serve on the Governance and Nominating Committee and the Audit Committee of the Board. Commenting on the appointment, Robert A. Bradway, Chairman and CEO of Amgen, said, "We are pleased to welcome Greg Garland to the Amgen Board. In addition to his leadership experiences as a chief executive officer, Greg brings more than 30 years of international experience in a highly regulated industry. At a time when Amgen is expanding its global presence to serve more patients, we look forward to Greg's contributions to the Board." The Full Research Report on Amgen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e96b_AMGN]

--

Celgene Corporation Research Report

On October 16, 2013, Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (Celgene), announced the results of MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) phase III clinical trial of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine. The Company informed that MPACT study is a Celgene-sponsored, open-label, randomized, study of 861 previously untreated patients with metastatic pancreatic cancer at 151 community and academic centers from 11 countries in North America. Markus Renschler, M.D., Corporate Vice President, Global Head of Hematology and Oncology Medical Affairs at Celgene, said, "The peer-reviewed publication of the MPACT results in the New England Journal of Medicine further validates the importance of this treatment regimen. These results led to the U.S. Food and Drug Administration's approval of ABRAXANE for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine." The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7f47_CELG]

--

Insys Therapeutics Inc. Research Report

On October 17, 2013, Insys Therapeutics Inc.'s (Insys) stock rose 12.68%, ending the day at $42.30. Over the previous three trading sessions, shares of Insys have gained 6.66%, outperforming the Nasdaq Composite which gained 1.25% during the same period. The Full Research Report on Insys Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/aabc_RCPT]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner